These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26481083)

  • 21. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension.
    White WB; Davidai G; Schumacher H
    J Hum Hypertens; 2009 Dec; 23(12):817-25. PubMed ID: 19357698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
    Redon J; Mancia G; Sleight P; Schumacher H; Gao P; Pogue J; Fagard R; Verdecchia P; Weber M; Böhm M; Williams B; Yusoff K; Teo K; Yusuf S;
    J Am Coll Cardiol; 2012 Jan; 59(1):74-83. PubMed ID: 22192672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
    Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
    Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial.
    Bosch J; Lonn EM; Dagenais GR; Gao P; Lopez-Jaramillo P; Zhu J; Pais P; Avezum A; Sliwa K; Chazova IE; Peters RJG; Held C; Yusoff K; Lewis BS; Toff WD; Khunti K; Reid CM; Leiter LA; Yusuf S; Hart RG
    Stroke; 2021 Aug; 52(8):2494-2501. PubMed ID: 33985364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. More HOPE for Prevention with Statins.
    Cushman WC; Goff DC
    N Engl J Med; 2016 May; 374(21):2085-7. PubMed ID: 27039666
    [No Abstract]   [Full Text] [Related]  

  • 29. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
    Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
    Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
    Weisser B; Gerwe M; Braun M; Funken C
    Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
    BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is very low dose hydrochlorothiazide combined with candesartan effective in uncontrolled hypertensive patients?
    Eguchi K; Hoshide S; Kabutoya T; Shimada K; Kario K
    Blood Press Monit; 2010 Dec; 15(6):308-11. PubMed ID: 20827176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial.
    Liu J; Wang B; Li Y; Yan X; Ge J; Li J
    Am Heart J; 2023 Mar; 257():93-102. PubMed ID: 36493840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
    Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
    MMW Fortschr Med; 2008 Feb; 150(6):40. PubMed ID: 18323344
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
    Suzuki H; Kanno Y;
    Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
    Bangalore S; Fayyad R; Messerli FH; Laskey R; DeMicco DA; Kastelein JJ; Waters DD
    Am J Cardiol; 2017 Feb; 119(3):379-387. PubMed ID: 27939230
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.